Personalis Inc. (NASDAQ:PSNL) received a favorable reimbursement decision that could make its cancer test available to more patients — and more likely to be paid for by Medicare.
The Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program expanded coverage for its NeXT Personal minimal residual disease test for breast cancer patients undergoing neoadjuvant therapy.
Something went wrong.
The new coverage determination applies to patients diagnosed with Stage II-III triple-negative breast cancer and HER2-positive breast cancer.
The decision allows clinicians to use the company's personalized circulating tumor DNA monitoring test to evaluate treatment response before surgery.
